Omeros Corp (OMER) Stock Price, Quote & News

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 676 5000

Website: www.omeros.com

Address:

The Omeros Building, 201 Elliott Avenue West, Seattle, United States

cdm85 Dec. 27 at 4:20 PM

$OMER Did some weekend digging and found Omeros CMS NTAP presentation earlier this December by doc Miguel Perales Nothing about the price itself but did find Omeros own 2027 TAM which they estimate to be 1100 patients. Omeros goal is to have positive cash flow in 2027. Burn around 25mill per Q equal ~ 100 mill annually. Yartemlea price must then be around 900k or higher?! Or do Novo millstones count in cashflow also or separate?? https://www.cms.gov/files/document/FY2027-NTAP-Town-Hall-Meeting-Transcript.pdf

4 · Reply

StockOrTwist Dec. 27 at 4:15 PM

$OMER https://www.youtube.com/watch?v=uDDngPcVB7k

0 · Reply

AgentMulder Dec. 27 at 4:04 PM

$OMER in addition to all the positives here, remember this is NOT OMER’S 1st rodeo! Extremely successful Omidria launch w/sufficient rev resulting in spin-off for 1B! The Ytar/Narso launch will be fast & efficient, & relationships w/docs already ongoing!! No dilution concerns, BS is strong going into ‘26! Going to be a YEAR TO REMEMBER for sure! Happy New Year Omerites & Omeros team 🎆 🎊🎈👍💪👍💪👍

0 · Reply

Jbaffs Dec. 27 at 3:47 PM

$OMER The reason they pushed back the CC till the 7th is for two reasons, 1) show they had an incredible kick off to sales, 2) show the pricing for the first time. BAM!!!!

1 · Reply

arodtx Dec. 27 at 3:43 PM

$OMER gotta be a PR on Friday about the launch right, they really were ready to hit the ground running 🙃

0 · Reply

Blueicecream Dec. 27 at 3:34 PM

$OMER This was a Christmas miracle. So many kids will live to be adults because of this FDA approval.

0 · Reply

capntrps Dec. 27 at 3:32 PM

$OMER so sick of all the idiots that say omer 'has' 2B from the novo deal. Likely never get that much, and or it will take forever. Great to have the second revenue source but people dont understand sh*t about actual finance/ financial modeling.

1 · Reply

minnguy64 Dec. 27 at 3:28 PM

$OMER - I think maybe the most interesting news gleaned from the week is of course the FDA approval. This isn't just some phase 2 or even phase 3 results that will still take years to develop and the interest falls away after a few days. THIS IS RIGHT NOW! And as important as that news is the second piece of fantastic information with this is the launch day which originally was hopefully sometime in January, is January 2nd. That's right -- in less than a week it is already being launched. They must have been gearing up for this ready to go just waiting on the approval because that just might be the fastest launch I have ever seen! Usually, after FDA approval the company has to do an offering to get the necessary funds for startup costs and then months later they can get it going, say May or June. By then, short term investors are long gone and the shorts pile in to take advantage. But in this case, the company is rapidly moving the launch and will be moving this a week from now!! Wow!!

3 · Reply

bombastic_ Dec. 27 at 2:40 PM

$OMER not sure what to make the cc delayed to January 7th? Speculation will brew for sure for this delayed cc. Almost always cc is same day or next day. Lost .

3 · Reply

_Brian1997_ Dec. 27 at 2:02 PM

What an insane trade, Thanks for keeping my month in the green. If you're looking for a good trader, Make sure to FOLLOW -> @ReversalFox . He's been on point with them entries. 💎 Watch for moves: $OMER $IZM $KXIN $GLSI too

0 · Reply

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Dec 24, 2025, 2:14 PM EST - 2 days ago

Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely

Dec 24, 2025, 12:21 PM EST - 3 days ago

Gold Edges Lower; Omeros Shares Jump

AAAU BAR DBP GLD GLDM IAU OUNZ

Dec 24, 2025, 9:05 AM EST - 3 days ago

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:00 AM EST - 3 days ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Dec 1, 2025, 8:30 AM EST - 26 days ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Nov 17, 2025, 10:37 AM EST - 5 weeks ago

Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:11 PM EST - 6 weeks ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 11, 2025, 8:30 AM EST - 6 weeks ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Oct 17, 2025, 4:43 PM EDT - 2 months ago

Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting

Oct 16, 2025, 10:08 AM EDT - 2 months ago

Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case

NVO

Oct 16, 2025, 8:30 AM EDT - 2 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 15, 2025, 2:58 PM EDT - 2 months ago

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

NVO

Oct 15, 2025, 11:54 AM EDT - 2 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 9:17 AM EDT - 2 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Oct 15, 2025, 8:32 AM EDT - 2 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Oct 15, 2025, 8:30 AM EDT - 2 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Sep 2, 2025, 8:45 AM EDT - 4 months ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Aug 19, 2025, 4:41 PM EDT - 4 months ago

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:02 PM EDT - 4 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:02 PM EDT - 4 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Jul 25, 2025, 8:00 AM EDT - 5 months ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jun 27, 2025, 8:30 AM EDT - 6 months ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 24, 2025, 8:30 AM EDT - 6 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Jun 10, 2025, 12:53 PM EDT - 7 months ago

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

May 27, 2025, 11:12 PM EDT - 7 months ago

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

May 27, 2025, 7:20 AM EDT - 7 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

AGL ANIP

May 15, 2025, 9:07 PM EDT - 8 months ago

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:05 PM EDT - 8 months ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 8 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 8 months ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 8 months ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 11, 2025, 3:06 PM EDT - 9 months ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 10, 2025, 9:10 AM EDT - 9 months ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 9 months ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 8:57 PM EDT - 9 months ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:02 PM EDT - 9 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 28, 2025, 7:39 AM EDT - 9 months ago

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Mar 26, 2025, 9:15 AM EDT - 9 months ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 10 months ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 24, 2025, 4:44 PM EST - 10 months ago

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Feb 20, 2025, 9:10 AM EST - 11 months ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 11 months ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 11 months ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 12:28 PM EST - 1 year ago

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 10, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 2, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Nov 21, 2024, 9:15 AM EST - 1 year ago

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

cdm85 Dec. 27 at 4:20 PM

4 · Reply

StockOrTwist Dec. 27 at 4:15 PM

$OMER https://www.youtube.com/watch?v=uDDngPcVB7k

0 · Reply

AgentMulder Dec. 27 at 4:04 PM

0 · Reply

Jbaffs Dec. 27 at 3:47 PM

$OMER The reason they pushed back the CC till the 7th is for two reasons, 1) show they had an incredible kick off to sales, 2) show the pricing for the first time. BAM!!!!

1 · Reply

arodtx Dec. 27 at 3:43 PM

$OMER gotta be a PR on Friday about the launch right, they really were ready to hit the ground running 🙃

0 · Reply

Blueicecream Dec. 27 at 3:34 PM

$OMER This was a Christmas miracle. So many kids will live to be adults because of this FDA approval.

0 · Reply

capntrps Dec. 27 at 3:32 PM

1 · Reply

minnguy64 Dec. 27 at 3:28 PM

3 · Reply

bombastic_ Dec. 27 at 2:40 PM

$OMER not sure what to make the cc delayed to January 7th? Speculation will brew for sure for this delayed cc. Almost always cc is same day or next day. Lost .

3 · Reply

_Brian1997_ Dec. 27 at 2:02 PM

0 · Reply

RidingUptrends Dec. 27 at 1:21 PM

$OMER conference call on the 7th?

0 · Reply

Blueicecream Dec. 27 at 12:19 PM

$OMER Read the full press release they announced its launching January 2nd but the conference call is a week later.

0 · Reply

ThreeGirls Dec. 27 at 12:18 PM

$OMER hey to Steve an others I was 100% wrong about those 2029 notes. They do in fact remain convertible. Which means OMER still has in the books $70M on the books. If the 2029 converts fully convert at $6.18, OMER issues ~11.4M shares — about 17% dilution — in exchange for eliminating $70.5M of debt. But the gloom and doom is overreach even if they did convert, especially with a share price far above the conversion price. Why? A) The dilution is already modeled • Analysts already include: • 11.4M potential shares • The market knows the notes are in the money • This is not a surprise issuance Any Hedged shares unwind cleanly. Thes were shares shorted as a hedge not directional shorts. If holders convert to shares they • Receive shares • Deliver them to close shorts This is: • Non-market selling • Not incremental supply hitting the tape

3 · Reply

Biotechinvestor101 Dec. 27 at 12:16 PM

$OMER NOVO logical ROW partner for narso, I would not be surprised if this was part kf the deal pending FDA approval.

1 · Reply

Kbm2000 Dec. 27 at 12:11 PM

$OMER any thoughts about the moved conference call - is it just because of the holidays or because more news are in the making?

1 · Reply

costrexx Dec. 27 at 11:42 AM

$OMER my wish list for next Monday. 1. Price of yartemlea being over $500,000 2. European partner announced 3. Share price doubles on the next day 😁

2 · Reply

cdm85 Dec. 27 at 11:41 AM

$OMER Here is Geminis response. Not that far off and 9 years after expenses only higher

0 · Reply

ThreeGirls Dec. 27 at 11:37 AM

$OMER Steve the bull, with 18K followers, still misleading all of you. He is insisting that the 2029 debt on th books is “convertible debt”, similar to the $67M that was just retired and a big dilution event is coming. He is wrong. In the May 2025 restructuring: • Certain existing convertible notes were exchanged • OMER issued NEW 2029 Notes • In exchange, noteholders received: • Higher cash interest (≈9.5%) • Later maturity (2029) • And what he is missing is the equity conversion feature was eliminated. What he fails to realize is restructuring traded equity optionality for cash yield and time. These new 2029 Notes are: • Senior unsecured debt • Cash interest only • Cash principal repayment at maturity • No holder option to convert into common stock • No conversion price • No share settlement mechanism There is simply NOTHING to convert, there is NO PENDING DILUTION EVENT coming from these notes, he is woefully misinformed and attempting scare you all. Don’t be.

0 · Reply

victor52155 Dec. 27 at 11:37 AM

$OMER The off label use should prove interesting in light of the mysterious placebo effect of the previous indication trial.

0 · Reply

JFais Dec. 27 at 10:46 AM

From Mike's weekly portfolio update (we both use a "tier system" for position sizing) $ARDX $OMER $KYTX $HROW

1 · Reply

cdm85 Dec. 27 at 10:37 AM

$OMER About pricing power for Yartemlea we will all know soon the exact price. Those who has been investors in the company long before narsoplimab became Yartemlea and the drug name was oms721 knows that Hsct/TA-TMA came on the rising early 2017 with promising results. 9 years later we have an approved drug. In 2017-2019 when CEO was turtoring the indication and why it made sense to pursuit he talk about the potential price. Back then, with no efficient treatment for TA-TMA and dieing patients just like today, pricing for trying to treat/poorly working management was already very very expensive. More expensive than the treatment for the underlying condition ex blood cancer. The number mentioned was ONE million dollars. Price for immune suppression like Solaris, defibrotide, intensive stay cost, bloodtranfusion ect ect All this summens up and all these expensenses will Yartemlea do significantly better both cost wise and also patient morbidity and mortality wise IMO price 500-750$

1 · Reply

MikeSmth Dec. 27 at 10:10 AM

$OMER Nice looking chart y'all. Hopefully the New Year will be as kind to my efforts to drag residential cellular concrete into code compliance. I've developing a retrofit system that would render a stick frame house hurricane and tornado proof. I'm still the same crackpot that a few of you remember though, so my chances are 50/50 at best lol. Seriously congrats, especially to Kreft and BanaT.

2 · Reply

Market Cap	1.09B
Revenue (ttm)	0.00
Net Income (ttm)	-156.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.80

Volume	7,151,700
Avg Vol	2,564,262
Day's Range	N/A - N/A
Shares Out	70.90M
Stochastic %K	79%
Beta	2.48
Analysts	Sell
Price Target	$33.67